CTIS2022-500256-37-00进行中（未招募）1 期
A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3-dose Regimen in 16- to 26-Year Old Women - V503-069
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •Boys and girls 9 to 15 years must not have had coitarche and do not plan on becoming sexually active during the vaccination period, Women 16 to 26 years who have never had a Papanicolaou (Pap) test or only have had normal Pap test results, Women 16 to 26 years with a lifetime history of 0 to 4 male and/or female sexual partners, Cohort 0 participants must have received 1 dose of 9vHPV vaccine at least 1 year prior to enrollment and did not receive a second dose of any HPV vaccine
排除标准
- •Known allergy to any vaccine component, Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial (Cohorts 1-5), History of severe allergic reaction that required medical intervention, Thrombocytopenia or any coagulation disorder, Females only: participant is pregnant or expecting to donate eggs during day 1 through month 7, Currently immunocompromised, or been diagnosed with immunodeficiency, Had a splenectomy, Receiving or has received immunosuppressive therapies within the last year, Received any immunoglobulin product or blood-derived product within 3 months, Has received more than 1 dose of an HPV vaccine (Cohort 0)
研究者
相似试验
进行中（未招募）
1 期
Safety and Immunogenicity of Extended 2-dose Regimens of 9vHPV VaccineMedDRA version: 20.0Level: HLGTClassification code 10047438Term: Viral infectious disordersSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: PTClassification code 10071146Term: Human papilloma virus immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2020-003736-24-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.700
进行中（未招募）
不适用
Phase 3, multicenter, multi-national, open-label study to evaluate the safety and efficacy of alfimeprase in subjects with occluded central venous access devices (sonoma-3) - NDCentral venous access device withdrawal occlusionMedDRA version: 9.1Level: SOCClassification code 10042613Term: Surgical and medical proceduresEUCTR2006-000545-19-ITVELO800
进行中（未招募）
不适用
A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/AParkinson's DiseaseEUCTR2004-000148-26-FISchwarz BioSciences Inc.360
进行中（未招募）
1 期
A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/AParkinson's DiseaseEUCTR2004-000148-26-ESSchwarz BioSciences Inc.360
进行中（未招募）
不适用
A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/AParkinson's DiseaseEUCTR2004-000148-26-SESchwarz BioSciences Inc.360